Derma Sciences Reports Fourth Quarter, Year-End Result...(current assets ...),Health

Date:4/1/2009

current assets 397,117 1,210,135 Total current assets 17,103,720 15,390,327 Cash - restricted 2,014,422 - Equipment and improvements, net 3,977,853 4,909,049 Goodwill 7,119,726 9,524,305 Other intangible assets, net 5,310,129 5,537,653 Other assets, net 681,472 509,507 Total Assets $36,207,322 $35,870,841 LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities Line of credit borrowings 3,446,605 1,219,197 Current maturities of long-term debt 1,298,207 1,288,532 Accounts payable 3,614,764 4,092,278 Accrued expenses and other current liabilities 2,004,493 3,421,282 Total current liabilities 10,364,069 10,021,289 Long-term debt 4,065,036 5,292,136 Other long-term liabilities 44,848 82,402 Deferred tax liability 340,871 420,059 Total Liabilities 14,814,824 15,815,886 Shareholders' Equity Convertible preferred stock, $.01 par value; 11,750,000 shares authorized; issued and outstanding: 2,280,407 at December 31, 2008 and 2007 (liquidation preference of $4,210,231 at December 31, 2008) 22,804 22,804 Common stock, $.01 par value, authorized shares 150,000,000; issued and outstanding shares: 40,140,743 at December 31, 2008 and 33,829,755 at December 31, 2007 401,407 338,298 Additional paid-in capital 40,027,645
'/>"/>

SOURCE Derma Sciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Derma Sciences to Report 2008 Fourth Quarter and Year-End Results on April 1, 2009
2. Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced
3. Wendy E. Roberts, MD, Named 2009-2010 President of the Womens Dermatologic Society
4. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
5. Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting
6. Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting
7. The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection
8. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
9. Professional Skin Care Company OrthoNeutrogena Becomes Ortho Dermatologics
10. American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies
11. Derma Sciences Gains FDA Clearance for Novel BIOGUARD(TM) Barrier Dressing with NIMBUS(R) Technology